title: Do human myeloma cells directly produce the receptor activator of nuclear factor kappaB ligand (RANKL) or induce RANKL in the bone marrow microenvironment?
authors.forename: Nicola
authors.initials: N
authors.lastname: Giuliani
authors.forename: Simona
authors.initials: S
authors.lastname: Colla
authors.forename: Vittorio
authors.initials: V
authors.lastname: Rizzoli
authors.forename: Sophie
authors.initials: S
authors.lastname: Barillé-Nion
authors.forename: Régis
authors.initials: R
authors.lastname: Bataille
mesh_terms: D001854:Bone Marrow Cells / Q000473:pathology*; D002352:Carrier Proteins / Q000235:genetics*; D016207:Cytokines / Q000235:genetics; D006801:Humans; D008024:Ligands; D008562:Membrane Glycoproteins / Q000235:genetics*; D009101:Multiple Myeloma / Q000235:genetics* / Q000473:pathology; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B
chemical_list: D002352:Carrier Proteins; D016207:Cytokines; D008024:Ligands; D008562:Membrane Glycoproteins; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; C505686:TNFRSF11A protein, human; C505688:TNFSF11 protein, human